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Close your eyes relax and enter in a darker side of your life 
Where you can best live your whishes, hopes and fantasies as well as your fears,  
Where you can be fully happy even when totally miserable, 
Where you can touch the untouchable, 
And where you can be sure that you are alive. 
I assure you that you will wish to come back every night. 
 
 Miguel Meira e Cruz, 2010 
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ABSTRACT  
 
Treatment of Obstructive Sleep Apneas With a Mandibular Advancement 
Device: A Preliminary Study about the Impact on Vigilance and Sleep Structure  
Miguel Meira e Cruz, Teresa Paiva 
Center of Electroecephalography and Clinical Neurophysiology 
Key-words: Obstructive sleep apnea, excessive somnolence, mandibular 
advancement devices 
Introduction: Obstructive sleep apnea-hypopnea syndrome (OSAHS) is a high 
prevalent and complex sleep disorder with serious consequences to individual 
and public health mainly because of its association with cardiovascular 
morbidity and mortality, sleep fragmentation and consequent excessive 
somnolence. The current American Academy of Sleep Medicine practice 
parameters recommends oral devices as a plausible option on the treatment of 
OSAHS. However, there is only a limited data about the efficacy of OSAHS 
treatment with prefabricated mandibular advancement devices (MAD) regarding 
to vigilance and sleep structure.  
Goals: The aim of this clinical prospective study was to evaluate the efficacy of 
a prefabricated mandibular advancement device in the treatment of OSAHS and 
to assess their impact on vigilance and sleep structure.  
Methodology: Nine patients (6 males and 3 females) with OSAHS (AHI > 5) 
recruited from a dental sleep consultation of a sleep clinic were referred to an 
attended full night polysomnographic study before and after treatment with 
MAD. Regarding to the therapeutic effect on OSAHS, an AHI < 5 events per 
hour of sleep after MAD treatment was considered to be a complete therapeutic 
response or therapeutic success whether an AHI < 50% from the baseline 
without achieving less than 5 events per hour was considered a partial 
response. Sleep structure and subjective sleepiness were assessed in order to 
evaluate the treatment efficacy. Wilcoxon matched pair test was used to test 
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differences between baseline and follow-up. A p-value of less than 0.05 was 
considered significant. 
Results:  Snoring was abolished or became inaudible in all patients as 
witnessed by their bed partners. There was an improvement on respiratory 
parameters from the baseline to the therapeutic PSG with 66.7% of patients 
achieving therapeutic success whereas 11.1% achieved only partial therapeutic 
response. Slow-wave sleep increased from 14% at the baseline to 21% after 
therapy with MAD and arousal index was lower after therapy (6/hr) than at 
baseline (16/hr) even though it was slightly above normal levels. All sleepiness 
scales scores and sleep complaints as well as sleep quality improved 
significantly after therapy compared with baseline (p<0.05). 
Conclusions: In this short-term study a titratable prefabricated MAD improved 
PSG respiratory parameters, sleep structure snoring and sleepiness in mild to 
moderate OSAHS patients thus supporting the use of this kind of option in 
OSAHS therapeutics. Future studies should focus on the comparison between a 
titratable prefabricated MAD with a placebo device as well as with a custom 
made MAD and also evaluate the long-term outcome. 
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Resumo (Portuguese Language) 
Tratamento da Apneia Obstrutiva do Sono com um dispositivo de avanço 
mandibular: Estudo preliminar sobre o impacto na vigília e na estrutura do 
sono 
Miguel Meira e Cruz, Teresa Paiva 
Centro de Electroencefalografia e Neurofisiologia Clínica 
Palavras-chave: Apneia obstrutiva do sono, sonolência excessiva, dispositivos 
de avanço mandibular 
Introdução: A síndrome de apneia-hipopneia obstrutiva do sono (OSAHS) é 
uma doença do sono com elevada prevalência e complexidade que afecta de 
forma importante a saúde individual e a saúde pública, principalmente pela sua 
associação com a morbilidade e mortalidade cardiovasculares, fragmentação 
do sono e consequente sonolência excessiva durante o dia. As recomendações 
actuais da American Academy of Sleep Medicine incluem os dispositivos orais 
enquanto opção viável para o tratamento da SAHOS. Contudo, são limitados os 
dados sobre a eficácia do tratamento da SAHOS com dispositivos de avanço 
mandibular pré-fabricados (DAM) no que respeita à vigília e no que respeita à 
estrutura do sono.  
Objectivos: O objectivo deste estudo clínico e prospectivo foi avaliar a eficácia 
de um dispositivo termoplástico de avanço mandibular no tratamento da 
SAHOS, bem como o impacto deste na vigília e na estrutura do sono. 
Metodologia: Nove pacientes (6 homens e 3 mulheres) com SAHOS (IAH > 5) 
recrutados de uma consulta de medicina dentária numa clínica de sono foram 
referenciados para um estudo polisonográfico antes e após tratamento com 
DAM. O sucesso terapêutico foi assumido com um IAH < 5 eventos por hora de 
sono após tratamento com DAM enquanto uma resposta parcial foi definida por 
IAH < 50% da linha de base sem que tenha sido atingido um valor menor que 5 
eventos por hora. Foram analisados a estrutura do sono e a sonolência de 
forma a avaliar a eficácia terapêutica. O teste de Wilcoxon foi usado para testar 
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a diferença entre as condições basal e terapêutica. Um valor de p menor que 
0.05 foi considerado como significativo. 
Resultados: O ressonar testemunhado pelos parceiros de cama foi abolido ou 
tornou-se inaudível em todos os pacientes. Existiu uma melhoria nos 
parâmetros respiratórios na PSG terapêutica comparada com a PSG basal, 
tendo 66.7% dos doentes atingido sucesso terapêutico enquanto 11.1% 
atingiram apenas resposta terapêutica. O sono de ondas lentas aumentou de 
14% na condição basal para 21% após terapia com DAM e o índice de 
despertares foi mais baixo após tratamento (6/h) do que na condição basal 
(16/h) embora tenha persistido ligeiramente superior ao normal. Todas as 
somas relativas a escalas de sonolência resultaram numa melhoria significativa 
após terapêutica com DAM. Todas as melhorias foram estatisticamente 
significativas (p<0.05).  
Conclusões: Neste estudo a curto prazo, os dispositivos pré-fabricados 
tituláveis melhoraram, de forma significativa, os parâmetros respiratórios 
polissonográficos, a estrutura do sono, a roncopatia e a sonolência nos doentes 
com SAOS ligeira e moderada apoiando a recomendação deste tipo de 
dispositivos para a terapêutica da SAHOS. Estudos futuros devem focar-se na 
comparação de dispositivos intra-orais pré-fabricados tituláveis com placebo e 
com dispositivos personalizados, e na avaliação dos efeitos destes dispositivos 
a longo prazo.      
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1. PREAMBLE 
 
The general aim of this master thesis entitled «Treatment of obstructive sleep 
apneas with a mandibular advancement device. A preliminary study about the 
impact on vigilance and sleep structure» was to evaluate the specific role of 
prefabricated Mandibular Advancement Devices (PF-MAD) in the treatment of 
obstructive sleep apnea-hypopnea syndrome (OSAHS) with focus on the 
influence in vigilance and sleep structure.  
Although many studies have evaluated the effect of MAD on sleep apneas and 
oxygenation status during sleep of OSAHS patients, there is little knowledge 
about their effects on characteristic symptoms among this condition. 
A prefabricated MAD was used in the present study because of three reasons: 
The first one was that although the use of prefabricated devices is not 
encouraged by official organs, these appliances are probably a frequent option 
when patients have no financial reimbursement for the treatment, which is the 
case for many countries today; 
Secondly most of the studies of prefabricated appliances used non-titratable 
devices, thus leading to a difficult interpretation about their isolated strengths 
and weaknesses; 
In third place, the evidence that also in mild cases of the disease there are 
already some chronic changes that will contribute to a multi-system 
degeneration turns plausible that patients could benefit from an early control of 
their condition with easily available treatment as mandibular advancement 
device, provided when another effective therapeutic option or positive airway 
pressure systems (PAPs) as continuous or automatic positive airway pressure 
(CPAP or APAP) are not indicated.  
Changes in sleep structure and in vigilance parameters were then analyzed in 
OSAH patients in order to adequately evaluate the therapeutic efficacy of a 
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specific mandibular advancement device in obstructive sleep apnea-hypopnea 
syndrome.  
In the introduction, there is a review of the literature, defining the theme, 
exposing the recent knowledge about general aspects related to OSAH, and 
positioning oral appliances therapy as an option to the treatment of this 
condition. 
After definition of the specific goals of this thesis, the methodology is described 
regarding patients selection criteria, protocol and instruments including statistic 
analysis. 
Finally, the results are presented and the discussion of those results is done in 
order to conclude about the hypotheses that were previously enhanced.    
 
 
 
 
 
 
 
 
 
 
 
 
P a g e  | 16 
 
 
2. Review of the Literature 
 
2.1 Sleep and its related disorders 
 
Sleep is a natural state of relatively suspended sensory and motor activity. This 
recurrent and vital period of our life time is characterized by total or partial loss 
of consciousness and mobility, accompanied by specific behavioral pattern as 
closed eyes and recumbent posture. It really consumes a third part of our lives 
and, inversely to what was thought until recently, sleep is a highly active rather 
than inactive process with a crucial role on physical and mental health (1). 
Although its primary function still remains to be discovered, the need of sleep is 
so powerful that we may be not able to avoid it even when doing so could be 
life-threatening, such as while driving. 
Sleep deprivation, either voluntary or involuntary, can be related to absent or 
decreased sleep and result in excessive sleepiness, changes in the mood, 
cognition, performance, cerebral function, cardiovascular disorders, endocrine 
function, metabolism and immune-inflammatory natural response. 
Sleep-related disorders, often characterized by sleep disruption and loss of 
consolidation, can be present in a variety of ways, including insomnia, 
excessive sleepiness, snoring, sleep apnea, cataplexy, sleep paralysis, sleep 
hallucinations, nocturnal dyspnea, nocturnal pain, and nocturnal physical 
phenomena (2).  
Sleep disorders cannot be however reduced to a poor night’s sleep problem. 
The most recent diagnostic classification divides sleep diagnosis into different 
categories: insomnias, sleep-related breathing disorders, hypersomnias, 
circadian rhythm sleep disorders, parasomnias, sleep related movement 
disorders, isolated symptoms, apparently normal variants and unresolved 
issues, other sleep disorders, sleep disorders associated with conditions 
classifiable elsewhere and other psychiatry/behavioral disorders frequently 
encountered in the differential diagnosis of sleep disorders (3). 
Sleep disorders, particularly those related to respiratory dysfunction are 
considered to be one of the most common health problems being estimated that 
between 82 and 98% of adults with these diseases are undiagnosed (4). 
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2.2 Obstructive sleep apnea hypopnea syndrome 
 
2.2.1 Definition and prevalence 
 
Obstructive sleep apnea-hypopnea syndrome (OSAHS) is a sleep related 
breathing disorder (SRBD) characterized by repetitive partial (hypopnea) or 
complete (apnea) interruptions of respiratory flux (fig.1) at upper airway level 
occurring during sleep with a minimum duration of ten seconds per event 
occurring at least five times per hour (5). This is one of the most common 
conditions observed in the practice of sleep medicine (6) with a high prevalence, 
occurring in about 4 % of the working male population and 2 % among the 
women (7).  
 
 
 
Fig.1 – Schematic view of airway obstruction during an event on OSAHS patient 
 
 
OSAHS is associated to a substantial negative impact on quality of life and 
productivity, due to an increased morbidity and mortality of cardiovascular 
diseases and sleepiness induced accidents (8). 
 
 
 
 
P a g e  | 18 
 
 
2.2.2 OSAHS Diagnosis  
 
The most frequent symptoms are diurnal hypersomnia, intense snore and 
witnessed respiratory pauses during sleep mostly associated to overweight and 
obesity (5), but neurocognitive, psychiatric, gastrointestinal genitourinary and 
endocrine or metabolic dysfunction are also common in patients with OSAHS. 
 
Although clinical features of OSAHS are very characteristic, the final diagnose 
requires a polysomnographic study (Fig. 2) which should ideally include sleep in 
all sleep stages and in all sleep positions, and should be at least 6 hours of 
duration (9). The apnea plus hyponea index (AHI – number of apneas plus 
hypopneas per hour of sleep) higher than 5, translates the first step of the 
complex condition commonly subsisting with clinical symptoms. Arousal events 
without criteria for classification within apneas or hypopneas are classified as 
respiratory effort related arousals (RERA) and should be taken in account when 
staging respiratory events. The AHI plus RERAS divided by total sleep time 
corresponds to the respiratory disturbance index (RDI) and reflects a more 
complete sleep respiratory status (3,9).    
 
 
 
Fig. 2 – Sample of attended PSG focusing two separated obstructive events 
(obstructive apnea, translated by the loss of signal on the airway flow channel) 
followed by EEG and EMG (chin and legs) arousal and accompanied by oxygen 
dessaturation. 
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2.2.3 Risk Factors 
 
Obesity is an important risk factor for SRBD and namely for OSAHS  by means 
of different mechanisms (10). An obese has 10-14 folds more risk of developing 
OSAHS than a non-obese has. However, this risk factor alone is not necessary 
for significant disease and there are other risk factors that can modify its effects. 
Important risk factors like neck circumference and craniofacial morphology and 
anthropometry are independently related to OSAHS, even in non-obese 
patients (10,11). 
 
Gender is a relevant risk factor too, being widely recognized that SRBD affect 
more men than women, what is related with anatomic as well as functional 
specific characteristics of each gender (12-14). Several studies found however a 
higher risk among women than what was though according to previous 
epidemiologic studies and that risk is clearly influenced by menopausal status 
(15-18)
. 
 
There are also ethnic differences in the prevalence of OSAHS and nonwhite 
individuals are more (and more severely) affected and at a younger age than 
Caucasian individuals (19, 20) although specific causes are not well clarified. 
 
Nasal obstruction was showed to negatively affect PSG parameters of 
respiratory status like AIH and arousal index in women, suggesting that it plays 
a role in worsening sleep apnea (21). Furthermore an association between 
chronic rhinitis with typical signs and symptoms of OSAHS was also found, 
even after adjustment for age, sex and BMI (22).  
  
Although there is no standardized phenotypic definition of OSAHS, several 
genetic and familial tendency associations have been emphasized from 
different perspectives suggesting that, apart from multiple indirect influences 
affecting obesity, body fat distribution and craniofacial morphology, genetics 
also play an independent role in OSAHS (23). 
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Age is other major risk factor for OSAHS, since both snoring and measured 
respiratory disturbance indices have tended to increase from youth to elderly. 
SRBD have a peak prevalence of 4.7% in the 50-59-year-old men group. The 
severity of the disease seem however to decrease in older people (24). 
 
Alcohol (25) and some medications (26) aggravate OSAHS by interfering in 
physiological control of OSAHS pathogenic associated mechanisms. Smoke 
also disturbs physiological sleep and particularly affect upper airway 
predisposing to OSAHS (27).      
 
2.2.4 OSAHS Treatment 
 
Apart from conservative therapeutic measures like weight reduction (28,29), 
avoidance of alcohol, pharmacological respiratory depressants and smoking (30), 
as well as sleep hygiene good habits (31) and some adjunctive measures (nasal 
decongestion and positional therapy) should be undertaken (32-34). At present, 
OSAHS therapy of choice is continuous or automatic positive airway pressure 
(CPAP or APAP) devices (35). However, especially in patients with a low AHI, 
positive pressure therapy is often complicated due to decreased acceptance 
and compliance by the patient. 
  
It has been shown that OSAHS therapy decreases the cardiovascular risk even 
in patients with only a moderately elevated RDI (36), providing a valuable 
argument to treat all the OSAHS patients, including those without indication to 
PAP therapy. In the last years oral appliances, in particular mandibular 
advancement devices (MAD) have been increasingly used in patient’s not 
sufficiently complying CPAP therapy or sometimes as first line therapy in non-
obese subjects.  
Actual data suggest that treatment with MAD increased the compliance due to a 
better acceptance, but that treatment success, measured either by AHI and RDI 
reduction is lower.  
Up to today there is only limited information about the impact of MAD treatment 
on sleep structure and vigilance (37) and although a recent Cochrane review 
concluded that there is some evidence suggesting oral appliances do improve 
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subjective sleepiness in patients with sleep related breathing disorders (SRBD), 
there are recognized limitations which were not only restricted to the small 
sample size but also to the under-reporting of methods and lack of some 
important parameters that should be controlled as quality of life evaluation (38).  
  
2.3 Daytime sleepiness in OSAH patients 
 
Excessive Sleepiness causing diurnal impairment is most often the primary 
complaint of patients presenting with sleep disorders. This can be associated to 
distinct factors among general individuals and is a common feature either in 
OSAHS or in cardiovascular disease patients (39).  
People are considered excessively sleepy when consistently experience 
difficulty to maintain wakefulness and alertness to accomplish the tasks of daily 
living. According to this, degree of sleepiness can be clinically classified in mild, 
moderate and severe (40).  
In OSAHS Patients, excessive sleepiness seems to be related with specific 
mechanisms affecting sleep consolidation related, although not exclusively, with 
intermittent hypoxia and consequent sleep fragmentation (41, 42). 
In general, individual subjective reports of sleepiness are imprecise, and 
objective and formal subjective measures of sleep have been devised to 
quantify the intensity of that symptom (43). Objective assessment of sleepiness 
severity can be achieved using different laboratorial tests like Multiple Sleep 
Latency Test (MSLT) and Maintenance of Wakefulness Test (MWT). Formal 
subjective measures are based on some kinds of sleepiness questionnaires 
which evaluate either acute (Stanford Sleepiness Scale or Karolinska 
Sleepiness Scale) or chronic states (Epworth Sleepiness Scale) (44-46).  
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2.4 Oral appliance therapy in OSAHS 
 
After its development in the early 1980s (47), the continuous positive airway 
pressure (CPAP) therapy became the gold standard therapy for symptomatic 
OSAH. It remains the first choice of most sleep medicine practitioners and there 
is very good evidence that effective CPAP improves the neurobehavioral and 
cardiovascular consequences of OSAH (48), sleepiness and sleepiness-related 
motor vehicle accidents (49,50) and quality of life (51). Otherwise, it is clear that 
effective CPAP therapy involves adherence as a critical target, since not all 
patients with OSAH accept or tolerate this treatment modality. Many studies 
show that considering as minimum compliance a regular use of CPAP for at 
least 4h per night, the success rate is between 46% and 85%, even when 
considering those sleepy patients with moderate or severe OSAH (52,53).  
Those rates tend to decrease when compliance is intended as a regular use of 
CPAP for more than 4 hours by night. Besides that, in asymptomatic snorers 
the rate of poor or no compliance to CPAP seems to be higher opening the 
scope for use of other treatments which could benefit patients. In this context a 
body of evidence exists towards the use of OA.  
It has been accepted by the American Academy of Sleep Medicine (AASM) in 
2005, and recently updated in the recommendations (2006) the use of OA as a 
first line treatment option of snoring and mild to moderate obstructive sleep 
apnea (54).  
OA constitutes a successful, easy and non invasive treatment option (or 
complement) for many patients with sleep related breathing disorders (55). 
Because they are simple to use and to manage, they are commonly and easily 
accepted by the majority of patients. However, due to poor knowledge of both 
dental professionals and other medical professionals, oral appliances are still an 
under prescribed option. 
The rational that propitiated the enthusiasm for therapeutic oral appliances is 
remote and its beginning may be reported to 1903, when was described that 
micrognathic infants could benefit when the tongue is sutured forward to the 
lower lip (56). Since then, there was a period during which helmets and 
chinstraps where used by physicians to reposition the mandible forward, and in 
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1934, the French stomathologist Pierre Robin reported the first use of an oral 
appliance to reposition the mandible in order to treat a case of glossoptosis due 
to atresia and hypertrophy of the mandible (57). Nevertheless, it was only almost 
50 years later that Cartwright and Samuelson used OA in order to manage 
snoring and sleep apnea with a specific OA (tongue retaining device) which is 
still in use (58). 
 
 
a. b. 
Fig. 3 - Bibloc Type Mandibular Advancement Devices: a. Thermolabyle 
(Somnofit, Oscimed); b. Custom made (MAS, Somnodent). 
 
 
 
 
a.                                                    b. 
Fig. 4 – Monobloc Type Mandibular Advancement Devices: a. 
Thermolabyle; b. Custom-made. 
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Fig. 5 - Tongue Retainer Device (TRD Aveo). 
 
 
2.4.1 Types and designs of oral appliances  
 
Currently, diverse assortment of designs and materials are being used in OA. 
Those oral devices can be classified in two main categories: MAD and tongue 
retaining devices (TRD). The first ones (Fig. 3 and 4) are the most commonly 
used in clinical practice and the scientific literature supporting their use and 
effects is far greater than for the other types of oral devices. Besides, if it is true 
that in the early 80s OA were indicated only in cases of CPAP or surgical 
failure, many investigations about the effectiveness and successful treatment of 
OSA with OA brought these devices (mainly, the MAD type) to the medical and 
scientific arena of today . They are now recognized as an excellent, evidence-
based option to a wide range of patients with SRBD, particularly patients with 
OSAHS.  
OA therapy, through the use of MADs is now indicated to several patients, from 
those non apneics with primary snoring to those with Upper Airway Resistance 
Syndrome (UARS) or airflow limitation, to those patients with definitive 
diagnosed OSAHS (59). 
 
 
2.4.1.1 Mandibular advancement devices (Fig. 3 and 4) 
 
MAD can be constructed with one piece (even called “monobloc”) or two pieces 
(“bibloc”) designs and may be custom-made or prefabricated (61). A monobloc 
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MAD rigidly fixes the mandible in an anterior position whereas a bibloc MAD 
allows for some freedom of mandibular movement, and is liable for individual 
titration. It is possible that because of this mechanism, this type of MAD is 
associated also with a lower rate of temporomandibular disorder and discomfort 
(60)
.  
While prefabricated MADs are appliances that only require a simple individual 
molding of a thermolabile material, custom-made appliances need well defined 
dental impressions, a bite registration and laboratory involvement. 
Although prefabricated MADs are not FDA approved as a definitive therapeutic 
and are only suggested for temporary use (61), they can be mainly useful in 
circumstances where patients are renitent to wear an expensive appliance 
without being sure of its full success or in circumstances in which patients 
cannot accede to an expensive solution without any reimbursement as happen 
with the majority of titratable custom made appliances. Furthermore, some 
evidence which serve the basis for the argument against the use of PF MADs in 
the continued treatment of SRBD seem to involve some bias since till now, the 
only study comparing effectiveness of PF MAD with custom made MAD actually 
compare a bibloc custom made type of appliance with a monobloc PF type of 
MAD (62), thus conducting to a conflicting interpretation of the results. Moreover, 
a very recent publication reported that titratable PF MADs were significantly 
more effective than non-titrable PF MAD either on objective or subjective 
outcomes regarding OSAHS improvement (63).   
  
A similar argument can be used with respect to mechanical retention. This 
property is essential for the successful treatment with a MAD, and it can be 
achieved, in upper and lower arch, by means of clasps, acrylic, or thermoplastic 
polymer embedded in the appliance, preventing the device pops up during the 
night due to masticatory muscles relaxation (64). Lack of retention is intended to 
be greater in PF MADs than in custom made MADs. However, the bias related 
to different appliance designs (bibloc versus monobloc) may also lead to difficult 
interpretations about the real independent effect related with the type of OA.  
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2.4.1.2 Tongue retaining devices (Fig. 5) 
 
TRD are appliances that reposition the tongue in an anterior position by 
securing it with negative pressure in a soft plastic bulb with or without restraint 
in the teeth. TRD can be useful as an alternative to MAD in some cases where 
this appliance cannot be successfully applied (due to insufficient retention 
related to extensive tooth loss, because an ongoing orthodontic treatment or the 
inability to get an adequate protrusion). However its full night application may be 
hampered by the shortness of the nasal passage, discomfort, or loss of 
negative pressure in the bulb.  
 
2.4.2 Oral appliances mechanisms of action 
 
The primary mechanism of action of a MAD is related with mandibular 
advancement, indirect anterior reposition of suprahyoid and genioglossal 
muscles, and the consequently movement of the tongue forward, increasing the 
anteroposterior dimensions of the oropharynx (65). However, it appears that the 
cross-sectional area of the velopharynx increases not only in the 
anteroposterior but also in the latero-lateral dimension, while the oropharynx 
increases mainly in the lateral dimension (66). Beside anatomical changes, MAD 
has a significant impact in neuromuscular properties of the upper airway and 
either both mandible rotation and advancement has been implicated in an 
increased muscle activity in the upper airway (67-70). 
The TRD mechanism of action is somewhat different: Although, usually 
reserved for patients in whom MAD is not indicated, the forward movement of 
the tongue out of the mouth tends to be greater and may produce more 
favorable changes in the retroglossal region. Otherwise, TRD seem to increase 
cross-sectional area of the upper airways during wakefulness (71) and to 
increase genioglossal muscle activity in OSAH patients (72), what possibly 
contributes to a reduction on snoring and apneic events. 
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                          a.          b. 
 
Fig. 6 - Lateral X-Ray from an OSA patient (a) and same patient using a 
mandibular advancement device (b) 
 
                              
 
Fig. 7 - Sleep Breathing Disorders Patient a) lateral regular photo; b) and c) 
using oral appliance 
 
2.4.3 Clinical outcomes of oral appliances therapy  
 
2.4.3.1 Effectiveness 
 
Oral appliance treatment goals involve not only the relief of the clinical signs 
and symptoms but also the normalization of polysomnographic parameters.  
Many OSA patients treated with MADs report less somnolence and snoring 
compared with their basal (not treated) condition. It is however important to be 
aware of different criteria defining success in the literature and to realize that 
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many subjective and objective parameters should be evaluated in order to 
securely recognize that a patient is being treated (not cured). Evidence related 
to MADs has shown that clinical symptoms such as excessive sleepiness, 
fatigue, snoring and non restorative or fragmented sleep improve with effective 
therapeutic measures. That should happen as well with measured 
polysomnographic associated events, like increased apnea-hypopnea index 
and respiratory effort related arousals (RERAs), increased oxy-hemoglobin 
dessaturation levels and increased microarousals (54). MAD therapy also 
associates to a significant increase of slow-wave and REM sleep (73,74).  
It is worth noting that patients commonly report subjective improvement without 
adequate improvement in PSG parameters (75). Considering however the risk 
associated to an unperceived increased in AHI and RDI, a follow up sleep study 
should always be conducted. 
Long term success studies of OA therapy show a high success rate after two to 
five years later (76-79) and demonstrate that a high number (80%) of patients 
initially successfully treated with OA, also experience a long term control of their 
OSAHS (80).  The success rate tends to decrease with time, what is usually 
related either to a failure in maintaining mandibular advancement in an optimal 
therapeutic position or to an increase in body weight (79-81). 
 
2.4.3.2 Oral Appliances therapy versus other treatments 
 
Since CPAP is the gold standard therapy for OSAHS, every study about 
success should imply comparison with CPAP treatment. In such studies, it is 
clear that although CPAP results better in reducing AHI particularly in patients 
with more severe disease (82-86), patients prefer MAD when both treatments are 
effective (84-88). Comparisons with other treatment options (surgical and non 
surgical) were made and discussed and, in all of them, effectiveness with OA 
was never inferior (89), being significantly superior in many important aspects of 
short (90) and long term success (77).  
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2.4.3.3 Impact of OA in the modification of health risks  
 
Two major complications of OSAHS (Cardiovascular and neurobehavioural) are 
related to intermittent hypoxic and sleep fragmentation mechanisms which lead 
to a sympathetic activation, blood pressure elevation, nitric oxide suppression 
and increase on oxidative stress, with consequent  endothelial dysfunction and 
eventual impairment of cardiovascular autonomic regulation (91,92). There is also 
evidence that in OSAHS patients free from cardiovascular disease there are 
already signs of arteriosclerosis (93). 
Although there is a lack of evidence about the effectiveness of OAs in many 
isolated vascular diseases, recent studies confirm the reduction of arterial 
pressure with MAD and it was showed that MAD reduces significantly the 
arterial pressure during the night when compared with CPAP or placebo (94-96) 
and that MAD therapy is also associated to an improvement of microvascular 
endothelial function (97).      
In a different level, other studies demonstrate that MAD improves 
neurocognitive function as mood disturbances, deficit of attention and memory 
(98)
 as well as quality of life (99). 
 
2.4.3.4 Oral Appliances as a co-adjuvant therapy 
 
The effectiveness of OA therapy in OSAHS was tested largely as a single 
treatment when other therapeutic resources failed. Its role as an adjuvant is 
being debated as well, and it is being proved that OA can be a viable option 
together with CPAP in some cases where it is pretended to reduce the pressure 
(100)
 or after surgery when outcome is not the expected one (101). On a similar 
perspective, when problems with PAP adherence persist, OAs can be used 
concomitantly or intermittently with PAP systems, probably providing better 
therapeutic outcomes either in mild, moderate or severe OSAHS (102). 
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2.4.3.5 Therapeutic compliance 
 
One of the major problems of a therapeutic decision is to guarantee a sufficient 
adherence in order to get an optimized response. Because of the importance of 
patient compliance knowledge, measures of compliance should be taken 
periodically. Nevertheless, in contrast to PAP systems, there is not a reliable 
method of compliance evaluation regarding OA thus treatment compliance must 
be subjectively measured. This can be usually achieved by means of an OA 
usage diary.   Meanwhile, either objectively or subjectively compliance 
measurements based studies show that a significant higher compliance is 
achieved with OA rather than with CPAP.  
One blind study (patients were blind to treatment purposes) in which was used 
a thermo sensitive device in order to get an objectively measurement of 14 days 
compliance to OA therapy, showed that the average compliance is 6,8 h of OA 
use per night. The same study has shown that there is an excellent agreement 
between objective and patient-reported compliance (103). In another study with 
patients self report of compliance (time and frequency of OA usage), 76% 
where compliant to a prefabricated monobloc OA whereas only 62% where 
compliant to CPAP (104). That tendency is being confirmed in some recent 
studies showing a significant higher compliance when patients are treated with 
OA (86%) than when those patients are treated with CPAP (67%) (105). 
Treatment compliance rate seems to have however a decrement over time 
which is variable. One study had been reported that after a four year period only 
32% of patients use appliance as prescribed (106) while other works show higher 
therapeutic adherence ranging from 48% to 76% after a two to five years (75, 77, 
79, 107)
. It is likely, however, that this decrement is related with the appliance 
specific design as well as the material characteristics, so it probably can be 
prevented with adequate follow-up, with correction of occurred time-dependent 
defects. 
There is a lack of studies comparing compliance between OA, however MADs 
are probably better than TRD (108, 109).  
Different conditions could affect compliance, and discontinuation of OA therapy 
is most of the times associated to side effects, treatment complications or the 
P a g e  | 31 
 
 
lack of self perceived benefits (110) but this association is however conflicting 
because of their common occurrence either in compliant and non compliant 
patients. 
 
2.4.3.6 Prediction of treatment response 
 
There is a wide variability within clinical and polysomnographic improvement 
among OA compliant patients: a high success is shown in a large number of 
studies, but some other studies have shown that about 30% of patients are 
under-treated (76). 
Clinical, polysomnographic and cephalometric features correlate with a better 
outcome of MAD therapy (60). Computed tomography, magnetic resonance 
imaging and endoscopy also appear to provide predictive information but their 
poor accessibility turns limited their use in a routine care basis.  
Disease severity (less severe), age (younger), weight (less obese), supine 
dependent events and reduced airway space are frequently (good) predictive 
parameters. 
  
2.4.3.7 Side effects 
 
The majority of side effects are usually temporary and related to OA type, usage 
frequency, degree of protrusion, clinical conditions or patient individual 
characteristics. They can vary from short-term to long-term respecting to the 
appearance of signs/symptoms, although the majority of them are considered 
midterm side effects as excessive salivation, dry mouth, tooth and jaw pain or 
discomfort and occlusion changes (76,81,108,111), thus requiring regular 
reevaluations in order to prevent traumatic lesions to the teeth and soft tissues.   
Longer-term side effects had however been reported in patients compliant to 
OAs. These are mainly related to dental and skeletal changes which could 
increase over time (112-114). In this context, overbite and overjet can be reduced 
and occlusion can open laterally. Patients with normal or mesial occlusion will 
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probably have unfavorable evolution, while patients with distal occlusion may 
benefit either from an orthodontic point of view and smaller changes are 
expected in patients with deeper bites (115,116). These effects are rather common, 
but usually small. The majority of the patients become accustomed to their 
slightly changed bite and considers that the treatment benefits largely 
overweigh the side effects. 
 
2.5 Clinical Protocol 
 
The international societies recommended approach for the initiation of OA 
therapy involves a prior specialized medical consultation, physical examination, 
some specific surveys, polysomnography and other complementary exams in 
order to diagnose the sleep problem and to discard other medical conditions.   
When a SRBD is diagnosed and OA is indicated, the responsible physician 
should refer the patient to a specialized sleep dentist. 
Sleep dental doctors should than perform a careful anamnesis, physical 
examination and be responsible for the prescription (or contraindication) and 
selection of the best oral appliance for the given condition. Apart from its 
specific role, dentists should also actively advise and monitor the general 
conditions and measures which can influence the clinical route as adherence to 
general measures, sleep hygiene, smoke habits and weight control.  
After insertion and adequate adjustment of OA, they also have to monitor the 
efficacy of the OA over time, which can be done either with subjective resources 
(e.g. scores like Epworth Sleepiness Scale and Visual analogue scale for 
somnolence and SF36 for the quality of life evaluation) and objective sleep 
recordings (sleep laboratory or ambulatory home recording). 
Particular attention should be given to the initial assessment and documentation 
of signs, symptoms, cast models and other exams, when necessary, in order to 
adequately compare and evaluate in the follow up visits.  
Short-term follow-up visits (to take place regularly from the date of appliance 
insertion to the 6th month) should be taken into account for adequately 
monitoring of compliance and of side effects and to titrate the OA till an optimal 
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position (often the “possible position”) (54,117). After that period patients should 
ideally return each 6 months in the first year and then every year afterwards (54).  
Economical factors may, however, influence this recommended regime. In this 
context, dentists can also have an important treatment role by systematically 
monitoring blood pressure, blood glucose and evaluating somnolence regularly 
as well as all other factors contributing to sleep related breathing disorders.  
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3. Rationale, Study Goals and Hypothesis 
 
As the introductory text emphasize, oral appliances, particularly mandibular 
advancement devices seem to play an important role in the treatment of sleep 
apnea patients with minor or any compliance to PAP systems or even as 
adjuvant to PAP therapy with lower pressure levels being necessary to achieve 
therapeutic success. It is however lacking evidence about the influence of oral 
appliances on reducing excessive somnolence among these patients. 
Given the high prevalence of PAP non-compliant patients, many of them with 
diurnal excessive somnolence which should be treated in order to promote 
individual and public health (avoiding accidents, labor failings, fatal mistakes), it 
is of major interest to understand the specific role of mandibular advancement 
devices in excessive somnolence of patients with sleep apnea syndrome. 
The main goal of this thesis is to evaluate if treatment of OSAHS with a specific 
thermolabile mandibular advancement device changes sleep structure and 
subjective vigilance parameters.  
 
3.1 Hypotheses of the study 
 
Motivated by the lack of evidence about the impact of oral appliance in daytime 
sleepiness of mild and moderate OSAHS patients, this study tested some 
scientific hypotheses regarding this therapeutic outcome. Therefore the null 
hypothesis (H0) and alternative Hypothesis (H1) are presented:  
H0: Treatment of OSAHS with a titratable prefabricated mandibular 
advancement device doesn’t have impact on vigilance and on sleep structure 
H1: Treatment of OSAHS with a titratable prefabricated mandibular 
advancement device has an impact on vigilance and on sleep structure 
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4. Methodology 
4.1 Patients selection criteria 
The diagnosis of OSAHS was based on a typical history, including complaints of 
excessive daytime sleepiness, habitual snoring, nocturnal apneas observed by 
the bed partner (if applicable), and a sleep study with an apnea-hypopnea index 
of at least 5 respiratory pauses per hour of sleep, or breathing patterns with 
signs of sleep-disruptive snoring combined with an elevated arousal index. 
The patients were treated with a mandibular advancement device because they 
were not eligible, had refused or did not tolerate nasal continuous positive 
airway pressure. 
Active dental or gingival disease was first treated, if necessary. 
Patients had to agree (gave written consent) with the regular use of the MAD 
and with the medical and follow-up examinations according to the protocol. 
 
Other inclusion criteria 
Ages between 35 and 60, Body Mass Index between 19 and 34.9 Kg/m2 and 
the existence of 8 healthy teeth or more per jaw (superior and inferior) without 
dentures or mobility and maximal protusion ability of at least 6 mm. 
 
Exclusion criteria 
Patients were excluded if they had other sleep disorders but the OSAHS, other 
severe or uncontrolled diseases, significant nasal obstruction and medicament 
therapy other than 1 antihypertensive drug or dental status not allowing 
mandibular advancement device insertion (abnormal dentition, acute dental 
lesion or periodontal infections or temporomandibular dysfunction according to 
the Helkimo index). Patients with a MAD compliance rate less than 50% of days 
usage were also excluded. 
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4.2 Measurements and Protocol 
 
4.2.1 Evaluation at baseline  
 
A general medical history and a careful dental examination were performed. 
Snoring and its impact was subjectively assessed trough a Portuguese version 
of the Thornton snoring scale. A Portuguese translation of the Epworth 
sleepiness scale, Karolinska Sleepiness Scale, Stanford Sleepiness Scale and 
Visual Analogue Scale were administered to evaluate the somnolence. 
Pittsburg Sleep Quality Index was administered to assess self perceived sleep 
quality.  
 
The diagnosis and severity of OSAHS were confirmed by in lab attended 
polysomnography with technical supervision. Sleep stages and arousals were 
scored according to AASM 2007 revised roles (117). An apnea and hypopnea 
were defined respectively as a decrease in the sum signal of the calibrated 
respiratory inductive plethysmograph to <= 50% of baseline and total absence 
of signal for more than 10 seconds with more than 4% of oxygen desaturation. 
Snore was defined by an excursion in the microphone channel that exceeded 
baseline noise by more than 50% and that was periodic with respiration. 
Lateral cephalometric radiographs and panoramic radiographs according to 
standard criteria were asked in order to access the anatomic features of the 
superior airway and to confirm the inexistence of maxillofacial and dental 
pathological findings, respectively. 
The Somnofit (from Oscimed – Switzerland) appliance is a titratable 
thermoplastic made two piece device joined by a plastic band supplied in 
different standard lengths, thus allowing corresponding levels of advancement.  
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In each patient a Somnofit device was fitted at the dental office after softened in 
warm water according to manufacturer instructions. The protrusion was initially 
set at 3 mm and, if necessary, adjusted according to the maintenance of 
symptoms and comfort of the patient.   
Patients were asked to register for one month (previous to the therapeutic 
PSG), the frequency of usage of the device by means of a simple usage diary in 
which they were asked to point out for each day, if they used the device in the 
night before. In this standardize diary, other topic respected to the amount of 
sleep in which patients used the device (all night, more than a half of the night, 
less than a half of the night). Another topic of this diary respected to self 
perceived degree of fatigue and/or somnolence comparing the baseline period 
with the therapeutic period (fatigue and/or somnolence is the same as before, 
better than before, worse than before). This diary make possible to get a 
relative compliance rate and a direct (although subjective) impact of the 
treatment continuity on patient. 
   
4.2.2 Evaluation after therapeutic PSG (with oral appliance) 
To evaluate effectiveness of mandibular advancement device therapy, patients 
were encouraged to use the oral device during 4 weeks before subsequent 
advancement. If needed (when major symptoms like witnessed snoring, 
witnessed respiratory pauses and excessive somnolence persists), subsequent 
advances were made, although limited to the pre-fabricated bands height (of 3, 
4.5, 6, 7.5, 9, 10.5 mm) and/or to the physiologic limited range of mandibular 
protrusion. MAD was considered “titrated” when no additional advance was 
needed because clinical improvement was achieved (significant reduction or 
cessation of symptoms) or no more advance was possible because of the 
anatomic and mechanical limitation. A polysomnography was then performed 
and all the questionnaires mentioned while the baseline evaluation were 
repeated.  Questions about possible side effects and their contribution to a 
probable treatment discontinuation were scored by a binominal scale (yes or 
no). 
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Treatment success (complete response) was defined by improvement of AHI 
from the baseline to less than 5 events per hour while partial response was 
defined by improvement of AHI in at least 50% from the baseline but not below 
5 and Epworth Sleepiness Scale score below than 10. All the other conditions 
were assumed as therapeutic failure. 
 
 
 
4.2.3 Instrument for subjective assessment of snoring  
 
Thornton Snoring Scale - TSS 
 
This scale is a self administered questionnaire with 5 questions that 
characterizes snoring and its social impact. TSS ask people to rate, on a 4 point 
scale (0-3) how snoring affects their relationship with the bed partner and other 
persons and how loud is their snoring. The total of TSS is the sum of 5 item-
scores and can range from 0 to 15. A score >= 5 highly suggest that snoring 
may be highly affecting quality of life. 
 
 
4.2.4 Instruments for sleepiness assessment  
 
Epworth Sleepiness Scale – ESS 
 
This scale is a self administered questionnaire with 8 questions that provides a 
measure of a person’s general level of daytime sleepiness, or their average 
sleep propensity in common circumstances during the month before. The ESS 
ask people to rate, on a 4 point scale (0 – 3), their usual chances of dozing off 
or falling asleep in 8 different situations or activities that most people engage in 
as part of their daily lives. The total ESS score is the sum of 8 item-scores and 
can range between 0 and 24. The higher the score, the higher the patients level 
of daytime sleepiness. A score >= 10 indicate sleepiness. 
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Stanford Sleepiness Scale – SSS  
 
Is a seven point Likert-type scale with descriptors ranging from “feeling active, 
vital alert, or wide awake” (score 1) to “no longer fighting sleep, sleep onset 
soon and having dream-like thoughts” (score 7). The patients should choose the 
descriptor which best describes their feeling of sleepiness at the time this scale 
is administered. 
For the purpose of this thesis, the punctuation was the mean of the 
measurements in three different periods of the same weekday (immediately 
after wake up, in the middle of the morning at 10 a.m, in the afternoon at 4 p.m). 
 
Karolinska Sleepiness Scale – KSS 
  
Is a standardized ten-level Likert-scale ranging from “very alert” (score 1) to 
“extremely sleepy” (score 10). The patients should choose the level that better 
adjusts to their feeling in the moment. The higher the score, the poorer is the 
alertness.   
For the purpose of this thesis, the punctuation was the mean of the 
measurements in three different periods of the same weekday (immediately 
after wake up, in the middle of the morning at 10 a.m, in the afternoon at 4 p.m). 
 
 
Pitsburg Sleep Quality Index – PSQI  
 
Is a self-administered questionnaire that is made up of 19 items in adition to five 
questions for the bed partner. The 19 items analyze different determinants of 
sleep quality grouped into seven components: quality, latency, duration, 
efficiency and sleep alterations, use of sleeping pill and daytime dysfunction 
whereas the last five questions are used to clinical information assessment but 
not to contribute for the total score of the index. Each component is scored from 
0 to 3 and the total score of PSQI is obtained from the sum of the seven 
components and ranges from 0 to 21 point (the higher the score, the worse the 
sleep quality). The usual cutoff value is 5 (>=5 reflect a bad sleep quality). 
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Visual Analogue Scale for sleepiness assessment – VAS 
 
Is a measurement instrument that tries to measure the amount of somnolence 
that a patient feels across a continuum of values within two extreme opposite 
meanings. Operationally is usually applied through the use of an horizontal line 
with 100 mm in length anchored by words reflecting two extreme and contrary 
conditions, e.g. Very alert and Very sleepy. 
The patient marks on the line the point that represents their perception of 
current state and the VAS score is determined by measuring in millimeters from 
the left end of the line to the point that patient marks. 
For the purpose of this thesis, VAS punctuation respect to the mean of three 
applications in different moments (immediately after wake, in the middle of the 
morning at 10 a.m, in the afternoon at 4 p.m). 
 
 
4.3 Data Analysis 
 
Statistics 
 
Computations were performed using the Statistical Package for Social Sciences 
(SPSS 17.0 for windows; SPSS Inc, Chicago). All statistical analyses employed 
2-tailed p values. 
Comparisons of corresponding mean values at successive time points were 
performed by Wilcoxon matched pairs test.  
Spearman rank correlation was used to determine the association between 
some variables.  
All tests were two-tailed and P values ≤.05 were considered statistically 
significant. 
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5. Ethical considerations 
 
The Ethics Committee of Lisbon Faculty of Medicine approved the study on 22 
of July 2009. 
All participants were given written and oral information about the study. All 
patients gave their informed consent. Furthermore, they were informed that their 
participation was voluntary and could be withdrawn by them at any time. The 
patients who declined to participate were respected without any explanations 
requested. 
The data were handled confidentially. All the results are presented in a way that 
ensures that it is not possible to identify any of the individuals. All patients were 
given the same information about the study at hand. We do not consider that 
participation in any of the studies can have had any negative consequences for 
the subjects included; rather they received more attention and assessment 
compared with common clinical handling. 
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6. Results Presentation 
6.1Descriptive Statistics 
Eleven Caucasian patients who met selection criteria were initially approached 
to participate and asked to give them informed consent. One patient withdrew 
from the study because of lack of previously defined minimum compliance as 
subjectively evaluated by the diary usage (< 50% of the days), and one patient 
was lost for follow up leaving a total of nine subjects (6 males and 3 females) 
with a mean age of 49 and ranging from 36 to 57 years old at baseline. 
 
 
 
 
 
Fig. 8 - Patients inclusion Flow chart 
 
Baseline Variables Mean Standard 
Deviation 
Min Max 
Mean Age (years) 48.8 7.3 36 57 
BMI (Kg/m2) 28.9 3.6 26.8 34.5 
Neck Diameter (cm) 37.0 2.5 33.5 40.0 
ESS (Epworth Sleepiness Scale) 11.1 4.2 5 18 
TSS (Thornton Snoring Scale) 8 3 3 13 
BMI – Body Mass Index; ESS – Epworth Sleepiness Scale; TSS – Thornton Snoring Scale 
 
Table 1.Characteristics of the study group at baseline (n=9). 
11 patients selected 
9 patients included 2 patients excluded 
1 lack of compliance 
1 lost for folow-up 
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There were no differences in average (p>0.05), regarding of Age, BMI and 
Neck diameter between Basal and MAD conditions. 
The mean induced mandibular advancement was 4.3 mm, with a median of 4.5 
mm (6 patients) and a minimum and maximum of 3 mm and 6 mm, respectively.  
The titration period (period between the diagnostic PSG and the last mandibular 
advancement before therapeutic PSG) was 19 weeks in average with a 
minimum of 0 (when patient was considered titrated with the very first 
advancement, as assessed by the clinical improvement after that) and a 
maximum of 48 weeks. The time between the start of treatment and the follow-
up sleep recording was 9.5 weeks in average, with a minimum of 4 and a 
maximum of 13 weeks. 
The mean amount of sleep at baseline as subjectively assessed by a sleep 
questionnaire was 443±11 on week days and 470±10 on weekends (p=0.02). 
6.2 Inferential Statistics 
 
Differences between Means 
 
SNORING 
COMPLAINTS 
BASELINE 
X           SD 
MAD 
X           SD 
Sig. 
 (p value) 
TSS 8 3 0 0 0.01 
TSS – Thornton Snoring Scale score 
Table 2.Snoring Score according to the Thornton Snoring Scale before 
(BASELINE) and after (MAD) treatment with mandibular advancement device 
(n=9) 
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Thornton Snoring Scale (TSS) 
TSS after treatment (0) was inferior to ESS before treatment (8). 
P < 0.05, meaning that existed significant statistical differences between two 
moments. 
Preliminary Conclusions: In this sample, there were differences between two 
moments regarding to snoring and snoring social negative impact assessed by 
TSS; snoring and snoring related social problems improved (were 
reduced) after treatment with MAD compared to basal condition.  
 
 
Graph. 1 - Boxplot Chart showing the differences between TSS score at the 
baseline and after therapy with MAD 
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ES Scores BASELINE 
Mean           SD 
MAD 
Mean           SD 
Sig. 
 (p value) 
ESS 11.1 4.2 9.2 4.3 0.02 
KSS 4.5 1.6 3.1 1.0 0.04 
SSS 2.9 0.9 2.1 0.8 0.01 
VAS 5.3 0.9 3.3 1.2 0.01 
ESS – Epworth Sleepiness Scale; KSS – Karolinska Sleepiness Scale; SSS – Stanford Sleepiness Scale; 
VAS – Visual Analogue Scale 
Table 6. Excessive somnolence (ES Scores) status before (BASELINE) and 
after (MAD) treatment with mandibular advancement device (n=9). 
 
 
 
  
 
SCORE 
BASELINE 
Mean           SD 
MAD 
Mean           SD 
Sig. 
 (p value) 
PSQI  8.2 1.7 4.4 2.0 0.01 
PSQI – Pitsburg Sleep Quality Index 
Table 7. Sleep Quality Index Total Score before and after treatment with 
mandibular advancement device (n=9) 
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Epworth Sleepiness Score (ESS) 
In average, ESS after treatment (9.2) was inferior to ESS before treatment 
(11.1). 
P < 0.05, meaning that existed significant statistical differences between two 
moments. 
Preliminary Conclusions: In this sample, there were differences between two 
moments regarding chronic excessive daytime sleepiness assessed by ESS; 
previous month (“chronic”) excessive sleepiness improved (was reduced) 
17.0% after treatment with MAD compared to basal condition.  
 
 
Graph. 17 - Boxplot Chart showing the differences between ESS score at the 
baseline and after therapy with MAD 
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Karolinska Sleepiness Scale (KSS) 
On average, KSS after treatment (3.1) was inferior to KSS before treatment 
(4.5). 
P < 0.05, meaning that existed significant statistical differences between two 
moments. 
Preliminary Conclusions: In this sample, there were differences between two 
moments regarding acute excessive daytime sleepiness assessed by KSS; 
acute daytime sleepiness improved (was reduced) 31.3% after treatment 
with MAD compared with baseline condition. 
 
 
Graph. 18 - Boxplot Chart showing the differences between KSS score at the 
baseline and after therapy with MAD 
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Stanford Sleepiness Scale (SSS) 
On average, SSS after treatment (2.1) was inferior to SSS before treatment 
(2.9). 
P < 0.05, meaning that existed significant statistical differences between the two 
moments. 
Preliminary Conclusions: In this sample, there were differences between two 
moments regarding acute daytime sleepiness assessed by SSS; acute 
daytime sleepiness improved (was reduced) 25.8% after treatment with MAD 
compared with baseline condition. 
 
 
Graph. 19 - Boxplot Chart showing the differences between SSS score at the 
baseline and after therapy with MAD 
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Visual Analogue Scale for Acute Sleepiness Assessment (VAS) 
On average, VAS score after treatment (3.3) was inferior to VAS score before 
treatment (5.3). 
P < 0.05, meaning that existed significant statistical differences between the two 
moments. 
Preliminary Conclusion: In this sample, there were differences between two 
moments regarding acute daytime sleepiness assessed by VAS for acute 
sleepiness assessment; acute daytime sleepiness improved (reduced) 
37.3% after treatment with MAD compared with baseline condition. 
 
 
Graph. 20 - Boxplot Chart showing the differences between VAS score at the 
baseline and after therapy with MAD 
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Pittsburg Sleep Quality Index (PSQI) 
On average, PSQI score after treatment (4.4) was inferior to PSQI score before 
treatment (8.2). 
P < 0.05, meaning that significant statistical differences existed between the two 
moments. 
Preliminary Conclusions: In this sample, there were differences between two 
moments regarding sleep quality assessed by PSQI; On average, sleep quality 
improved (there was a lower PSQI score) in 46.0% after treatment with MAD, 
compared with basal condition.  
 
 
Graph. 21 - Boxplot Chart showing the differences between PSQI score at the 
baseline and after therapy with MAD 
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PSG 
Sleep Mac 
BASELINE 
X           SD 
MAD 
X           SD 
Sig. 
 (p value) 
TST (min) 417 54 409 49 0.95 
SE    (%) 83 9 84 8 0.44 
SL    (min) 29 24 16 8.1 0.09  
SLR (min) 158 72 96 51 0.14 
N1    (%) 15 10 9 3 0.14 
N2    (%) 55 15 49 9.1 0.26 
N3    (%) 14 7.4 21 8.3 0.05 
R      (%) 15 7.7 21 7.7 0.09 
TST – Total Sleep Time; SE – Sleep Eficiency; SL – Sleep Latency; SLR – Sleep Latency to REM Sleep 
Stage; N1 – N1 Sleep Stage; N2 – N2 Sleep Stage; N3 – N3 Sleep Stage 
Table 3.PSG Sleep macrostructure (Sleep Mac) components status before 
(BASELINE) and after (MAD) treatment with mandibular advancement device 
(n=9) 
 
 
Total Sleep Time (TST) 
TST after treatment (409 min) was inferior to TST before treatment (417 min)  
P > 0.05, meaning that existed no significant statistical differences between two 
moments. 
Preliminary Conclusion: In this sample, there were no differences between 
TST before and after treatment with MAD.  
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Graph. 1 - Boxplot Chart showing the differences between TST at the baseline 
and after therapy with MAD 
 
 
Sleep Efficiency (SE) 
SE after treatment (84%) was superior to SE before treatment (83%). 
P > 0.05, meaning that existed no significant statistical differences between two 
moments. 
Preliminary Conclusion: In this sample, there were no differences between SE 
before and after treatment with MAD.  
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Graph. 2 - Boxplot Chart showing the differences between SE at the baseline 
and after therapy with MAD 
 
Sleep Latency (SL) 
SL after treatment (16 min) was inferior to SE before treatment (29 min). 
P > 0.05, meaning that existed no significant statistical differences between two 
moments. 
Preliminary Conclusion: In this sample, there were no differences between SL 
before and after treatment with MAD; a trend for a lower sleep latency was 
however observed after treatment with MAD (p=0.09). 
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Graph. 3 - Boxplot Chart showing the differences between SL at the baseline 
and after therapy with MAD 
 
Sleep Latency to REM sleep stage (SLR) 
SLR after treatment (96 min) was inferior to SLR before treatment (158 min). 
P > 0.05, meaning that existed no significant statistical differences between two 
moments. 
Preliminary Conclusion: In this sample, there were no differences between 
SLR before and after treatment with MAD although there was a trend. 
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Graph. 4 - Boxplot Chart showing the differences between SLR at the baseline 
and after therapy with MAD 
 
N1 sleep stage (N1) 
The relative amount N1 sleep stage after treatment (9%) was inferior to the 
relative amount of N1 sleep stage before treatment (15%), in average. 
P > 0.05, meaning that existed no significant statistical differences between two 
moments. 
Preliminary Conclusion: In this sample, there were no differences between the 
relative amount of N1 sleep stage before and after treatment with MAD. 
P a g e  | 56 
 
 
 
 
Graph. 5 - Boxplot Chart showing the differences between amount of N1 sleep 
stage at the baseline and after therapy with MAD 
 
N2 sleep stage (N2) 
The relative amount N2 sleep stage after treatment (49%) was inferior to the 
relative amount of N2 sleep stage before treatment (55%), in average. 
P > 0.05, meaning that existed no significant statistical differences between two 
moments. 
Preliminary Conclusion: In this sample, there were no differences between the 
relative amount of N2 sleep before and after treatment with MAD. 
P a g e  | 57 
 
 
 
 
Graph. 6 - Boxplot Chart showing the differences between amount of N2 sleep 
stage at the baseline and after therapy with MAD 
 
N3 sleep stage (N3) 
The relative amount of N3 sleep stage after treatment (21%) was superior to the 
relative amount N3 sleep stage before treatment (14%), in average. 
P = 0.05, meaning that existed significant statistical differences between two 
moments 
Preliminary Conclusions: In this sample, there were differences between two 
moments; relative amount of N3 sleep stage after treatment with MAD was 
higher than the relative amount of N3 sleep stage in the basal condition. 
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Graph. 7 - Boxplot Chart showing the differences between amount of N3 sleep 
stage at the baseline and after therapy with MAD 
REM sleep stage (R) 
The relative amount of REM sleep stage after treatment (21%) was superior to 
the relative amount of REM sleep before treatment (15%). 
P > 0.05, meaning that existed significant statistical differences between the two 
moments. 
Preliminary Conclusion: In this sample, there were no differences between 
relative amount of REM sleep before and after treatment with MAD; a trend for 
a higher amount of REM sleep was however observed after treatment with 
MAD (p=0.09). 
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Graph. 8 - Boxplot Chart showing the differences between amount of N3 sleep 
stage at the baseline and after therapy with MAD 
 
 
PSG 
Sleep Mic 
BASELINE 
Mean           SD 
MAD 
Mean           SD 
Sig. 
 (p value) 
Arousals 16.3 13.6 6.0 2.8 0.01 
PLMi 13.9 28.8 4.1 7.8 0.62 (NS) 
Arousals – Arousal Index; PLMi – Periodic Leg Movements Index 
Table 4. PSG Sleep microstructure (Mic - microarousals and periodic leg 
movements) status before (BASELINE) and after (MAD) treatment with 
mandibular advancement device (n=9) 
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Arousal Index (Arousals) 
In average, the arousal index after treatment (6/h) was inferior to the arousal 
index before treatment (16.3/h). 
P < 0.05, meaning that significant statistical differences existed between the two 
moments. 
Preliminary Conclusions: In this sample, there were differences between two 
moments regarding arousal index; in average, arousal index improved 63.3% 
after treatment with MAD, compared with the basal condition. 
 
 
 
Graph. 9 - Boxplot Chart showing the differences between arousal index at the 
baseline and after therapy with MAD 
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Periodic Leg Movements Index (PLMi) 
In average, PLMi after treatment (4.1/h) was inferior to the PLMi before 
treatment (13.9/h). 
P > 0.05, meaning that there were no statistical significant differences between 
the two moments. 
Preliminary Conclusion: In this sample, there were no differences in periodic 
leg movement index before and after treatment with MAD. 
 
Graph. 10 - Boxplot Chart showing the differences between periodic leg 
movements index at the baseline and after therapy with MAD 
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PSG 
Respiratory 
BASELINE 
Mean           SD 
MAD 
Mean           SD 
Sig. 
 (p value) 
AHI (events/h) 11.6 8.6 4.8 4.0 0.02 
OEI (events/h) 15.4 16.5 4.4 4.0 0.05 
AI (events/h) 7.1 9.1 1.5 1.8 0.02 
MeanO2Sat (%) 95.0 1.0 94.8 2.1 0.67 
MinO2Sat (%) 83.6 6.5 81.9 12.7 0.86 
ODI (events/h) 9.4 5.2 4.4 4.0 0.03 
AHI – Apnea Hypopnea Index; OEI – Obstructive Events Index; AI – Apnea Index; MeanO2Sat – Mean 
Oxygen Saturation (%); MinO2Sat – Minimum Oxygen Saturation (%); ODI – Oxygen Dessaturation Index 
Table 5. PSG respiratory status before (BASELINE) and after (MAD) 
treatmentwith mandibular advancement device (n=9) 
 
Polysomnographic Respiratory Status 
Apnea + Hypopnea Index (AHI) 
In average, the AHI after the treatment (4.8/h) was inferior to AHI at the 
baseline (11.6/h). 
P < 0.05, meaning that there were significant statistical differences between the 
two moments. 
Preliminary Conclusions: In this sample, there were differences between the 
two moments regarding to AHI; in average, AHI improved (decreased) 58.9% 
after treatment with MAD compared to the baseline condition. 
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Graph. 11 - Boxplot Chart showing the differences between Apnea-Hypopnea 
Index at the baseline and after therapy with MAD 
 
Obstructive Events Index (OEI) 
In average, OEI after treatment (4.4/h) was inferior to AHI at the baseline 
(15.4/h). 
P = 0.05, meaning that there were significant statistical differences between the 
two moments of OEI assessment. 
Preliminary Conclusions: In this sample, there were differences between the 
two moments of evaluation regarding to OEI; in average, OEI improved 
(decreased) in 71.5% after treatment with MAD compared to the baseline 
condition. 
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Graph. 12 - Boxplot Chart showing the differences between Obstructive Events 
(apneas plus hypopneas) Index at the baseline and after therapy with MAD 
 
Apnea Index (AI) 
In average, AI after treatment (1.5/h) was inferior to AI at the baseline (7.1/h). 
P < 0.05, meaning that existed significant statistical differences between the two 
moments of AI assessment. 
Preliminary Conclusions: in this sample, there were differences between the 
two moments of evaluation regarding to AI; in average, AI improved 
(decreased) in 78.8% after treatment with MAD compared to the baseline 
condition 
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Graph. 13 - Boxplot Chart showing the differences between Obstructive Apneas 
Index at the baseline and after therapy with MAD 
 
Sleep Mean Oxy-hemoglobin Saturation (MeanO2Sat) 
In average, MeanO2Sat after treatment (94.8) was inferior to MeanO2Sat 
before treatment (95.0). 
P > 0.05, meaning that there were no significant statistical differences between 
the two moments. 
Preliminary Conclusion: in this sample, there were no differences between 
sleep mean oxy-hemoglobin saturation before and after treatment with MAD. 
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Graph. 14 - Boxplot Chart showing the differences between Mean Oxy-
hemoglobin Saturation at the baseline and after therapy with MAD 
 
Sleep Minimum Oxy-hemoglobin Saturation (MinO2Sat) 
In average, MinO2Sat saturation after treatment (81.9) was inferior to MinO2Sat 
before treatment (83.6).  
P > 0.05, meaning that there were no significant statistical differences between 
the two moments. 
Preliminary Conclusion: in this sample, there were no differences between 
sleep minimum oxy-hemoglobin saturation before and after treatment with MAD. 
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Graph. 15 - Boxplot Chart showing the differences between Minimum Oxy-
hemoglobin Saturation at the baseline and after therapy with MAD 
Oxy-hemoglobin Dessaturation Index (ODI) 
In average, ODI after treatment (4.4/h) was inferior to ODI before treatment 
(9.4/h). 
P < 0.05, meaning that existed significant statistical differences between the two 
moments. 
Preliminary Conclusions: In this sample, there were differences between the 
two moments regarding to Oxygen desaturation index; ODI improved (was 
decreased) in 52.9% after treatment with MAD compared to the baseline 
condition. 
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Graph. 16 - Boxplot Chart showing the differences between Oxygen 
Desaturation Index at the baseline and after therapy with MAD 
 
Distribution pattern regarding AHI classes at baseline and after treatment 
 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
 5≤AHI 
<15   
7 77,8 77,8 77,8 
AHI≥15 2 22,2 22,2 100,0 
Total 9 100,0 100,0  
 
Table 7. Frequency table of patients defined by AHI severity class at baseline  
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Graph. 22 - Pie Chart illustrating AHI class distribution at the baseline 
 
 
 
 
 
  
Frequency Percent Valid Percent 
Cumulative 
Percent 
 AHI <5 6 66,7 66,7 66,7 
5≤AHI 
<15 
3 33,3 33,3 100,0 
Total 9 100,0 100,0  
 
Table 8. Frequency table of patients defined by AHI severity class after 
treatment with MAD 
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Graph. 23 - Pie Chart illustrating AHI class distribution after treatment with MAD 
 
At baseline the study group was composed by 77.8% of patients classified as 
mild apneics (AHI>5 and <15) and 22.2% of patients classified as moderate to 
severe apneics (AHI>15). 
After treatment with MAD, the study group was composed by 66.7% non 
apneics (AHI<5) and 33.3% of mild apneics. No moderate to severely apneics 
persisted after MAD therapy. 
Preliminary Conclusion: There were differences in the distribution pattern of 
patients regarding to AHI severity between baseline and after MAD therapy 
When analyzed on the basis of an intention to treat technique, the success rate 
was 6/11 = 54.5% in “the worst case scenario”, if it is presumed that patients 
who were lost to follow-up failed to achieve therapeutic success; while in the 
“best case scenario”, the success rate was 8/11 = 72.7%. 
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Compliance Rate Assessment 
 
Regarding to the regularity of treatment, 55.6% of patients which were included 
in the study were fully compliant to the treatment (used MAD for 100% of the 
nights) whereas 44.4% used MAD for at least 50% of the nights during the 
study. 
From those patients with a full compliance rate, 80% used MAD for the entire 
night of sleep each night whereas 20% used it for at least 50% of each night 
time, on average. 
From those patients with a compliance rate between 50% and 100%, 75% of 
them used MAD for the entire night of sleep, each night whereas 25% of 
patients used it for at least 50% each night time, on average. 
 
 
Graph. 24 - Illustration of relative compliance rate (% of nights with MAD) in 
patients using the MAD for all the nights of the study 
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Graph. 25 - Illustration of relative compliance rate (% of the night with MAD) 
in patients using the MAD for more than 50% but less than 100% of the 
nights  
 
Compliance rate as analyzed by intention to treat method was 5/11 = 45.5% in 
“the worst case scenario”, if it is presumed that patients who were lost to follow-
up failed to be fully compliant as defined by the use of MAD for 100% of the 
nights; while in the “best case scenario”, the success rate was 7/11 = 63.6%. 
 
Side effects 
Regarding to side effects 44.4% (n=4) of patients complained of at least one 
minor and temporary side effect (excessive salivation, dry mouth, gum irritation, 
occlusal changes in the morning-after and discomfort) while undergoing MAD 
therapy with occlusal changes in the morning after, and discomfort being the 
more frequent complaints in 22.2% of patients (n=2).      
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Association between variables 
Association between anthropometric and respiratory variables was tested for 
BMI, neck circumference, AHI and OEI before treatment. There was also tested 
the association between all those parameters in the therapeutic condition and 
compliance rate. The association between AHI, amount of mandibular 
advancement and side effects was tested in order to evaluate a possible 
interdependency role between those parameters. 
  
A negative correlation between BMI and MeanO2Sat (r=-0.07; p=0.03) was 
found in the basal condition.    
A positive correlation between neck circumference and AHI (r=0.72; p=0.03) 
was found in therapeutic condition. 
A positive correlation between neck circumference and OEI (r=0.74; p=0.02) 
was found in therapeutic condition.  
Compliance rate was negatively correlated with AHI (r=-0.78; p=0.01) in the 
therapeutic condition. 
A positive correlation between occlusal changes in the morning after and AHI 
(r=0.73; p=0.03) was found in the therapeutic condition. 
A positive correlation between discomfort complaint and AHI (r=0.73; p=0.03) 
was found in the therapeutic condition. 
A positive higher correlation between occlusal changes in the morning after and 
amount of mandibular advancement (r=0.87; p=0.003) was found in the 
therapeutic condition. 
A positive higher correlation between discomfort complaint and amount of 
mandibular advancement (r=0.87; p=0.003) was found in the therapeutic 
condition.   
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7. DISCUSSION 
 
7.1. Clinical and demographic characterization 
OSAHS symptoms have a major adverse impact on both the individual and 
public health. Even thought that prefabricated MADs are not recommended as a 
long-term therapeutic option, at this time there is no other certified titratable OA 
available in Portugal and despite the deployment of custom made OA 
manufactured in a foreign country like Spain or Germany, the main fact they are 
significantly more expensive and has no insurance or national health system 
coverage did patients opt for that modality. 
The present investigation provides data about the direct positive effect of a 
titratable prefabricated mandibular advancement device on sleepiness and 
sleep structure in OSAHS patients. 
Although with some limitation because of the small number of patients, the 
sample of this study was demographically comparable to that in most of other 
studies which evaluated the efficacy of mandibular advancement devices in 
OSAHS.  
The mean age of patients included (48.8 years old) was within the range of the 
maximum prevalence of OSAHS and was comparable to that found by Bixler et 
al (24). 
 
The mean body mass index among patients of this study (28.9 Kg/m2) was in 
the range of overweight (>25 and <29.9) and mean neck circumference (37 cm) 
is lower than that intended as contributing for a significant increased risk for 
OSAH (higher than 41 cm) (118). These data are consistent with findings of the 
most of the studies about OSAHS and were similar to those of other important 
prevalence study showing that increased BMI and neck circumference are 
associated to an overall risk in a “dose-response” manner (29), even thought we 
couldn’t found any correlation between these two risk factors and even between 
each one and apnea-hypopnea index. Furthermore there was only a slight (p=-
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0.07), although significant (p=0.03) negative correlation between basal BMI and 
MeanO2Sat.   
 
The baseline mean Epworth Sleepiness Scale score of this sample was slightly 
higher than 10 (11.1) which is positive for excessive sleepiness. Like was 
showed in other works (119,120), this data support that sleepiness is a common 
finding either in mild or moderate OSAH cases. 
 
7.2. Comparison between baseline and after treatment with MAD 
 
Regarding age, BMI and neck circumference, there were no significant 
differences between the two occasions (before and after treatment) thus 
reducing external variables that could influence the final results of this study. 
 
Some studies suggest that a MAD derives its therapeutic effect mainly from the 
amount mandibular advancement imposed by the appliance (99, 118). However, 
although diverse protocols have been proposed in order to adequately titrate a 
MAD (121, 122), none is optimal since they only takes into account the respiratory 
parameters and subjective complaints but not the EEG (123) or even the EMG  
(124)
 signal which in some cases may associate to and reflect a hidden 
respiratory impairment. On the other hand, since oral appliance on-lab titration 
can disturb physiologic sleep it is probably not the indicated method for assess 
sleep therapeutic neurophysiologic structure as pointed by Friedman et al (63).  
We have also recognized this limitation and since it remains impossible to meet 
an optimized titration (the ideal protrusion of the mandible) of MAD without 
continuous follow-up sleep studies which could verify the improvement of sleep 
parameters associated with mandibular advancement on each moment, some 
uncertainty persisted related to the optimal position; i.e.  the minimal possible 
protrusion that was needed to achieve the best possible improvement of 
objective sleep variables.  
The fact that only clinical status and subjective evaluation served the base to 
decide when to finish titration could result in loss of some effects which would 
be expected. On the other hand, it was showed that, despite an inadequate 
improvement in the AHI, OSAHS patients may report clinical amelioration, 
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mainly when initiating oral-appliance therapy, even at a sub-optimal titration 
level (76).     
 
In this study, compliance rate was slightly lower than it was reported in previous 
studies (103 -105). This can be related to a more strict definition of compliance than 
that used in other works (use of MAD in 100% of the nights and for all night). On 
the other hand since the symptoms (mainly those related to daytime 
impairment) were very slight in this sample (with a mean baseline ESS=11), it is 
not so surprising that a lower rate of compliance could be reported. However, 
compliance rate observed in our study was similar to that reported by Friedman 
and colleagues (63) also with a titratable prefabricated MAD. 
 
 
Respiratory Status 
 
The therapeutic effect of a MAD in the treatment of obstructive sleep apnea-
hypopnea syndrome is variable and the success rate varies among samples 
according to the definition used (68, 76, 125-128). 
Concerning the respiratory status, the results demonstrated that mandibular 
advancement device used in this study was statistically effective, with an 
average of 58.9% significantly reduction in AHI from the baseline, reaching 
normal levels (<5/h). If only obstructive events index (OEI) was analyzed, an 
average improvement of 71.5% was observed. Regarding apnea index, there 
was a 78.8% reduction in number of apneas per hour of sleep from baseline. 
According to what was previously defined, in this study, treatment Success 
(AHI<5) was obtained in 6 patients (66.7%) and partial response (50% 
reduction in AHI from the baseline and ESS<10 but AHI>5) was observed in 1 
patient. Failure was found in 2 patients (22.2%). 
The overall response rate observed in this study (77.8%) is consistent with the 
results from other works reviewing this issue (129) although slightly higher than 
that reported by Friedman et al (62.1%). It is possible that the higher severity 
(higher AHI) of OSAHS and the higher BMI observed on Friedman study could 
explain those differences. Otherwise, a probable (not reported by the authors of 
that work) higher neck circumference within more severe patients might be an 
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influencing factor as we have found that neck circumference correlates well with 
AHI and OEI. 
 
Some relevant findings were the significant positive correlation between neck 
circumference and AHI (r=0.72; p=0.03) and particularly between neck 
circumference and OEI (r=0.74; p=0.02). Moreover, there was no association 
between BMI and AHI after therapy with MAD.  
This findings highly suggests that success rate of OSAHS treatment with 
mandibular advancement devices is probably more dependent from cervical 
volume, particularly fat mass volume, than from BMI, at least in mild to 
moderate sleep apnea patients. 
 
Mean oxygen saturation and minimum oxygen saturation remained unchanged 
but the number of oxygen desaturations per hour of sleep (ODI) significantly 
improved (52.92% reduction from baseline). This is in accordance with previous 
results and a positive influence of the MAD; i.e. on reduce intermittent nightly 
hypoxia in OSAHS patients (76). 
 
Sleep Macrostructure 
 
Total sleep time after treatment with MAD was not different from that observed 
at baseline (p=0.95). It was reduced compared to normal values on both 
occasions (<7h). Although other studies have showed the same trend (130), is 
hard to scrutinize whether this particular result reflected a lack of influence of 
MAD on TST because the majority of patients who participated in this project 
needed to wake up early to go work thus intentionally reducing total time in bed 
and probably TST. This later hypothesis is supported by the significant 
differences found between subjectively assessed amount of sleep on week 
days (443 min) and on weekends (470 min) (p=0.02). 
 
Sleep efficiency after treatment with MAD was not different from that observed 
in the baseline (p=0.44) although it was below the normal (<85%) on both 
occasions of evaluation. This can be explained either by the aforementioned 
“intentional” reduction of TST, by the repeated arousals probably related with 
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the hassle of wires from the polysomnogram. It can also be explained by a first-
night effect which can be related to the increased fragmentation of sleep 
architecture as showed by Lorenzo and Barbanoj (131). These two later factors 
can also explain why arousal index persisted at an abnormal elevated level 
(>5/h), although there was a significant improvement from the baseline (16.3/h) 
to the therapeutic PSG (6/h) (p=0.01).  
 
Neither sleep latency nor sleep latency to REM sleep onset showed differences 
between the two moments studied. 
 
Regarding the percentage of sleep in various stages, significant differences 
were only founded regarding slow wave-sleep (N3) which increased after 
therapy with MAD (p=0.05); to slightly above normal levels (>20%). This 
probably reflects a compensation for previous slow-wave sleep deprivation. This 
result is in agreement with previous findings supporting that oral appliances 
increase slow-wave sleep (74,75).    
The percentage of N1 stage had on both occasions an abnormal duration 
(>5%). The percentage of N2 stage was normal (45%-55%) before treatment 
and doesn’t have changed with MAD (p>0.05). 
  
REM Sleep stage duration showed an improvement trend (p=0.09), reaching 
normal percentage (20%-25%) after MAD therapy. This had also been showed 
in other studies (128) and probably associates to a rebound of REM sleep in 
subjects who were previously REM deprived.  
 
Sleep Microstructure 
 
After treatment with MAD, patients had an important and significant decrease in 
microarousals (16.3 to 6; p=0.01) although those events persisted slightly 
above the normal pattern (<5/h). Similar results have been obtained by other 
groups with regard to the effect of MAD on arousal index (128, 130) and, in the 
absence of a reduction on TST, this probable contributes to a better clinical 
outcome regarding to the alertness state that is higher in MAD group compared 
to the baseline.   
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Periodic Limb Movements (PLMs) also reduced from the baseline to the 
therapeutic PSG. Although reaching normality, differences were not statistically 
significant (p>0.05). This trend is supported by findings of Gindre et al. (121). 
Neverthless, in a recent paper Guerrero et al. (124) reported that PLMs can 
appear during MAD treatment and warned for the possibility of these periodic 
movements could be associated to the residual sleepiness which is sometimes 
observed in patients treated with MAD. 
 
Subjective Daytime Sleepiness 
 
Clinical symptoms of somnolence as reported by patients were better after MAD 
therapy than at baseline. Subjective daytime sleepiness as assessed either by 
ESS, KSS, SSS or VAS was significantly improved (p<0.05) in these patients. 
Epworth Sleepiness Scale score improved significantly from 11 to 9 (p=0.02) 
what is an important finding since it was not very high at the baseline. 
Acute Sleepiness, either assessed by Karolinska Sleepiness Scale, Stanford 
Sleepiness Scale or Visual Analogue Scale showed a significantly improvement 
of 31.3%, 25.8% and 37.3%, respectively (p=0.04, p=0.01 and p=0.01). 
General Sleep Complaints as measured by Pittsburg Sleep Quality Index was 
significantly (p=0.01) decreased from the baseline. 
Whereas the magnitude of improvement in subjective sleepiness with the MAD 
in our study sample was highly significant, the clinical relevance of those results 
must be carefully evaluated since the main limitation of any subjective report is 
that it is open to response bias. It is otherwise possible that a placebo effect can 
influence those results as noted by Gotsopoulos and colleagues (124). 
 
Side effects 
 
In this study, patients only reported minor and temporary (less than 1 month of 
duration) side effects with occlusal changes in the morning after as well as 
discomfort being the most common complaints. These side effects were 
reported from only 2 patients. Either low percentage of side effects and 
characteristics of side effects reported in this study were in agreement with 
usual short-term complaints (104).  
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The positive association that was found between AHI and complaints of side 
effects as well as between these adverse effects and amount of mandibular 
protrusion contrasts with findings of some previous studies (112) although is 
supported by others (132). It is however important to note that since this was a 
short-term study, it was less likely to find important persistent occlusal changes 
even if they tend to present later in the course of treatment. 
 
 
7.3 Final note and future directions 
 
Even though there were some limitations, an important aspect of this study is 
related to the fact that it was based on a real-life scenario, both as regards the 
availability of options and both with regard to the financial capacity of patients 
thus leading to a potential practical application of evidence gathered. The 
positive results of this therapeutic option need to be confirmed in larger 
populations and compared with other treatment modalities and placebo. Studies 
using prospective randomized and controlled designs with longer folow-up 
should be undertaken in order to adequately assess the real therapeutic 
potential and limitations of titratable prefabricated oral appliances. 
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8. CONCLUSION 
 
The tested null hypothesis is rejected since we found significant improvements 
in respiratory parameters (AHI, OEI and ODI), objective sleep structure 
parameters (N3 sleep stage improvement and reduction of arousal index) and 
subjective vigilance parameters (ESS, KSS and VAS).  
This study showed that a titratable prefabricated Mandibular Advancement 
Device has an important role on the treatment of Obstructive Sleep Apnea-
Hypopnea Syndrome since it could improve clinical and laboratorial outcomes.  
This study also showed that an adjustable thermolabile MAD can improve sleep 
structure and sleepiness in mild to moderate OSAHS patients on a significant 
manner thus supporting the use of this kind of MAD in patients indicated for oral 
appliances who doesn’t have financial capabilities to afford custom made 
appliances which are significantly more expensive and not reimbursed by 
insurance companies neither by the Portuguese public health System.  Further 
research is however desirable to confirm the present results because of the 
small sample size in the present study. Future studies should compare the 
titratable prefabricated MAD with a placebo and custom made adjustable 
devices. Furthermore the long-term effects and side effects of this type of MAD 
should be assessed.  
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Appendix 1 – Thornton Snoring Scale (Adapted Portuguese Version) 
 
ESCALA DE RONCOPATIA DE THORNTON  
 
Se ressona, isso não o afecta apenas a si pela privação de um sono recuperador. O 
seu ressonar também afecta as pessoas que convivem consigo. A escala de 
roncopatia de Thornton (na sua versão adaptada para Português de Portugal) ajuda-
o(a) a determinar de que forma o seu ressonar pode estar a afectar as pessoas que 
convivem consigo. Escolha o número mais apropriado para cada situação tendo em 
conta a sua realidade habitual. Apesar de cada situação poder ser distinta, se a soma 
de pontos for igual ou superior a 5, sugerimos que consulte o seu médico. 
 
• 0 = Nunca 
• 1 = Raramente (1 noite por semana) 
• 2 = Com alguma frequência (2-3 noites por semana) 
• 3 = A maior parte do tempo (4 ou mais noites por semana) 
 
1. O meu ressonar afecta a relação com o meu parceiro   □ 
 
2. O meu ressonar contribui para que o meu parceiro esteja   □ 
irritável ou cansado 
 
3. O meu ressonar contribui para que eu e o meu parceiro    □ 
tenhamos que dormir em quartos separados 
 
4. O meu ressonar é intenso (no som)      □ 
 
5. O meu ressonar afecta as pessoas quando durmo fora de casa  □ 
 
 
Pontuação Total:         ___   
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Appendix 2 – Epworth Sleepiness Scale (Adapted Portuguese Version) 
 
 
 
 
Com base na pontuação possível (0 = nada provável adormecer; 1 = pouco 
provável adormecer; 2 = probabilidade moderada de adormecer; 3 = alta 
probabilidade de adormecer) classifique a que melhor se lhe adapta à forma 
como no último mês se sentiu ou se sentiria (caso não tenha feito) em cada 
uma das opções seguintes. 
                  Probabilidade 
1. Sentado a ler        __ 
2. A ver televisão        __ 
3. Sentado, inactivo, num local público (cinema, reunião,etc…) __ 
4. Como passageiro num carro durante uma hora sem intervalo __ 
5. Sentado a conversar com alguém     __ 
6. Sentado calmamente após o almoço sem álcool   __ 
7. Num carro, como condutor parado por minutos num semáforo __ 
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Appendix 3 – Stanford Sleepiness Scale (Adapted Portuguese Version) 
 
Por favor, marque a opção (com uma bola envolvendo o nº) que mais se 
adequa ao seu estado nas 3 situações descritas: 
 
a. Ao despertar 
 
1. Sentindo activo, com vitalidade, alerta ou claramente acordado 
2. Funcionando em níveis altos mas não no pico; Apto para se concentrar 
3. Acordado mas relaxado; Com capacidade de resposta mas não 
totalmente alerta 
4. Algo mole, sentindo-se em baixo 
5. Mole, perdendo o interesse em manter-se acordado 
6. Sonolento, zonzo, lutando contra o sono, preferindo dormir 
7. Já não luta contra o sono, o sono iniciará dentro de momentos, 
pensamentos do sonhar-acordado 
8. Dormindo 
 
 
b. A meio da manhã 
 
1. Sentindo activo, com vitalidade, alerta ou claramente acordado 
2. Funcionando em níveis altos mas não no pico; Apto para se concentrar 
3. Acordado mas relaxado; Com capacidade de resposta mas não 
totalmente alerta 
4. Algo mole, sentindo-se em baixo 
5. Mole, perdendo o interesse em manter-se acordado 
6. Sonolento, zonzo, lutando contra o sono, preferindo dormir 
7. Já não luta contra o sono, o sono iniciará dentro de momentos, 
pensamentos do sonhar-acordado 
8. Dormindo 
 
C. A meio da tarde 
1. Sentindo activo, com vitalidade, alerta ou claramente acordado 
2. Funcionando em níveis altos mas não no pico; Apto para se concentrar 
3. Acordado mas relaxado; Com capacidade de resposta mas não 
totalmente alerta 
4. Algo mole, sentindo-se em baixo 
5. Mole, perdendo o interesse em manter-se acordado 
6. Sonolento, zonzo, lutando contra o sono, preferindo dormir 
7. Já não luta contra o sono, o sono iniciará dentro de momentos, 
pensamentos do sonhar-acordado 
8. Dormindo 
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Appendix 4 - Karolinska Sleepiness Scale (Adapted Portuguese Version) 
 
Por favor marque a opção (uma bola por volta do número correspondente) que 
mais se adequa ao seu estado nos últimos 10 minutos: 
a. Ao despertar 
 
1. Extremamente alerta 
2. Muito alerta 
3. Alerta 
4. Pouco alerta 
5. Nem alerta nem sonolento 
6. Com alguns sinais de sonolência 
7. Sonolento mas sem esforço para manter acordado 
8. Sonolento com algum esforço para manter acordado 
9. Muito sonolento, com grande esforço para manter acordado, lutando 
contra o sono 
10. Extremamente sonolento, sem conseguir manter acordado 
 
b. A meio da manhã 
 
1. Extremamente alerta 
2. Muito alerta 
3. Alerta 
4. Pouco alerta 
5. Nem alerta nem sonolento 
6. Com alguns sinais de sonolência 
7. Sonolento mas sem esforço para manter acordado 
8. Sonolento com algum esforço para manter acordado 
9. Muito sonolento, com grande esforço para manter acordado, lutando 
contra o sono 
10. Extremamente sonolento, sem conseguir manter acordado 
 
c. A meio da tarde 
 
1. Extremamente alerta 
2. Muito alerta 
3. Alerta 
4. Pouco alerta 
5. Nem alerta nem sonolento 
6. Com alguns sinais de sonolência 
7. Sonolento mas sem esforço para manter acordado 
8. Sonolento com algum esforço para manter acordado 
9. Muito sonolento, com grande esforço para manter acordado, lutando 
contra o sono 
10. Extremamente sonolento, sem conseguir manter acordado 
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Appendix 5 – Pittsburgh Sleep Quality Index Questionnaire (Adapted 
Portuguese Version) 
 
INDICE DE QUALIDADE DO SONO DE PITTSBURGH 
(VERSÃO PORTUGUESA ADAPTADA) 
 
Nome: _______________________________________________________________ 
 
Registo: _____________  Idade: _______ Data: ___________ Hora: ________ 
 
Instruções: 
As perguntas seguintes referem-se aos seus hábitos de sono mais frequentes, apenas 
durante o último mês. As suas respostas devem indicar a recordação mais exacta da 
maioria dos dias e noitesno último mês. Por favor responda a todas as questões. 
 
1. Durante o último mês, a que horas geralmente foi para a cama? 
Hora normal de deitar: __________ 
 
2. Durante o último mês, quanto tempo (em minutos) levou para adormecer 
em cada noite? 
Número de minutos: ____________ 
 
3. Durante o ùltimo mês, a que horas geralmente se levantou de manhã? 
 
Hora de levantar: ______________ 
 
4. Durante o último mês, quantas horas de sono teve por noite? (Isto pode 
ser diferente do número de horas que ficou na cama) 
Horas de sono por noite: _________ 
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Para cada uma das questões restantes, marque a melhor. Por favor 
responda a todas as perguntas: 
 
5. Durante o último mês, com que frequência teve dificuldade em dormir 
porque... 
 
a) Não conseguiu dormir em até 30 minutos 
 Nunca no último mês ____ 
 Menos de 1 vez/ semana ____ 
 1 ou 2 vezes/ semana ____ 
 3 ou mais vezes/ semana ____ 
 
b) Acordou a meio da noite ou de manhã cedo 
 Nunca no último mês ____ 
 Menos de 1 vez/ semana ____ 
 1 ou 2 vezes/ semana ____ 
 3 ou mais vezes/ semana ____ 
 
c) Precisou de se levantar para ir à casa de banho 
 Nunca no último mês ____  
 Menos de 1 vez/ semana ____ 
 1 ou 2 vezes/ semana ____ 
 3 ou mais vezes/ semana ____ 
 
 
d) Não conseguiu respirar de forma confortável 
 Nunca no último mês ____ 
 Menos de 1 vez/ semana ____ 
 1 ou 2 vezes/ semana ____ 
 3 ou mais vezes/ semana ____ 
 
e) Tossiu ou ressonou intensamente 
 Nunca no último mês ____ 
 Menos de 1 vez/ semana ____ 
 1 ou 2 vezes/ semana ____ 
 3 ou mais vezes/ semana ____ 
 
f) Sentiu muito frio 
 Nunca no último mês ____ 
 Menos de 1 vez/ semana ____ 
 1 ou 2 vezes/ semana ____ 
 3 mais vezes/ semana ____ 
 
g) Sentiu muito calor 
 Nunca no último mês ____ 
 Menos de 1 vez/ semana ____ 
 1 ou 2 vezes/ semana ____ 
 3 ou mais vezes/ semana ____ 
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h) Teve sonhos maus 
 Nunca no último mês ____ 
 Menos de 1 vez/ semana ____ 
 1 ou 2 vezes/ semana ____ 
 3 ou mais vezes/ semana ____ 
 
i) Teve dor 
 Nunca no último mês ____ 
 Menos de 1 vez/ semana ____ 
 1 ou 2 vezes/ semana ____ 
 3 ou mais vezes/ semana ____ 
 
j) Outra(s) razão(ões), por favor descreva _______________ 
________________________________________________. 
 
Com que frequência, durante o último mês, teve dificuldade para dormir 
devido a essa razão? 
Nunca no último mês ____ 
Menos de 1 vez/ semana ____ 
1 ou 2 vezes/ semana ____ 
3 ou mais vezes/ semana ____ 
 
6. Durante o último mês, como classificaria de uma maneira geral a qualidade do 
seu sono? 
Muito boa ____ 
Boa ____ 
Má ____ 
Muito má ____ 
 
7. Durante o último mês, com que frequência tomou medicamentos para o/a 
ajudar a dormir (prescritos ou por conta própria)? 
 
Nunca no último mês ____ 
Menos de 1 vez/ semana ____ 
1 ou 2 vezes/ semana ____ 
3 ou mais vezes/ semana ____ 
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8. No último mês, com que frequência teve dificuldade em manter-se acordado/a 
enquanto dirigia, comia ou participava de uma actividade social (festa, reunião 
de amigos, trabalho, estudo)? 
 
Nunca no último mês ____ 
Menos de 1 vez/ semana ____ 
1 ou 2 vezes/ semana ____ 
3 ou mais vezes/ semana ____ 
 
9. Durante o último mês, quão dificil lhe foi manter o entusiasmo (ânimo) para 
fazer as coisas (as suas actividades habituais)? 
Nenhuma dificuldade ____ 
Dificuldade muito ligeira ____ 
Dificuldade razoável ____ 
Grande dificuldade ____ 
 
10. Você tem um parceiro (esposo/a) ou colega de quarto? 
Não ____ 
Parceiro ou colega, mas noutro quarto ____ 
Parceiro no mesmo quarto, mas não na mesma cama ____ 
Parceiro na mesma cama ____ 
 
Se tem um/a parceiro/a ou colega de quarto, pergunte-lhe com que frequência, no 
último mês, você teve ... 
a) Ressonar forte 
 
Nunca no último mês ____ 
Menos de 1 vez/ semana ____ 
1 ou 2 vezes/ semana ____ 
3 ou mais vezes/ semana ____ 
 
b) Longas paragens respiratórias enquanto dormir 
 
Nunca no último mês ____ 
Menos de 1 vez/ semana ____ 
1 ou 2 vezes/ semana ____ 
3 ou mais vezes/ semana ____ 
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c) Contracções ou esticões nas pernas enquanto dormia 
 
Nunca no último mês ____ 
Menos de 1 vez/ semana ____ 
1 ou 2 vezes/ semana ____ 
3 ou mais vezes/ semana ____ 
 
d) Episódios de desorientação ou confusão durante o sono 
 
Nunca no último mês ____ 
Menos de 1 vez/ semana ____ 
1 ou 2 vezes/ semana ____ 
3 ou mais vezes/ semana ____ 
 
e) Outras alterações(inquietações) enquanto dorme; por favor, descreva 
____________________________________________________________
___. 
 
Nunca no último mês ____ 
Menos de 1 vez/ semana ____ 
1 ou 2 vezes/ semana ____ 
3 ou mais vezes/ semana ____ 
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Appendix 6 – Diary of Oral Appliance Usage Questionnaire 
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Appendix 7 – Informed Consent Letter of acceptance 
 
Consentimento Informado 
 
 
1. Título do Projecto. 
  
Tratamento das apneias obstrutivas com um dispositivo de avanço mandibular. 
Estudo preliminar sobre o impacto na vigília e na estrutura do sono                                                              
 
O presente documento visa fornecer-lhe a informação básica de que depende o 
seu consentimento para a participação voluntária neste projecto de 
investigação. O presente documento é um requisito necessário para essa 
participação. Pede-se que o leia, coloque as suas dúvidas a quem lho 
apresenta e, se quiser participar, assine o documento. Leve o tempo que 
entender necessário para examiná-lo. 
 
 
2. Descrição sucinta da natureza, objectivos e procedimentos do estudo. 
                                                                                                                                                                       
Este é um estudo clínico, prospectivo, que pretende avaliar o impacto dos 
dispositivos intra-orais de avanço mandibular na estrutura (qualidade) do sono 
e nos factores de vigília (sintomas diurnos/sonolência diurna). 
 
De acordo com o protocolo do estudo, a terapêutica de avanço mandibular será 
realizada através de aparelhos de avanço mandibular em dois blocos (superior 
e inferior) termo-moldáveis e ajustáveis. O efeito terapêutico deste dispositivo 
relaciona-se com a diminuição da compressão mecânica das vias aéreas 
superiores pelos tecidos duros e moles da orofaringe.  
 
O aparelho ser-lhe-á colocado após uma consulta médico-dentária de 
avaliação e a protrusão da mandibula relativamente à base do crânio será 
ajustada num intervalo de conforto e objectivando uma optimização anatómico-
fisiológica para que se verifique uma boa permeabilidade das vias aéreas (de 
forma a que se processe normalmente a função respiratória). 
 
A terapêutica com dispositivos orais de avanço mandibular pode associar-se a 
efeitos adversos, sendo estes normalmente de gravidade ligeira e de curta 
duração. Os efeitos adversos mais comuns são alteração na mordida, 
salivação excessiva, boca seca e incómodo ligeiro. 
 
Os investigadores assumem a responsabilidade pela confidencialidade de 
quaisquer dados recolhidos. 
 
Dada a voluntariedade da sua participação, é-lhe possível desvincular-se a 
todo o tempo do presente processo de investigação, sendo que tanto a recusa 
inicial como o abandono subsequente não acarretam qualquer penalização ou 
perda de direitos. 
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Se subsistirem algumas dúvidas ou forem necessários esclarecimentos 
suplementares previamente à sua participação, poderá contactar: 
 
Nome  Dr. Miguel Meira e Cruz (Médico Dentista, Coordenador do 
Projecto) 
Local  Centro de Electroencefalografia e Neurofisiologia Clinica 
Telefone 213715450 
e-mail   mmc@gentesaudavel.pt 
 
 
 
_________________________________________________ 
(Assinatura legível do responsável pela investigação) 
 
 
 
Tomo conhecimento, não tenho dúvidas e aceito participar no projecto dando,  
por via da minha assinatura, o consentimento informado e esclarecido 
 
 
_________________________________________________ 
(Assinatura do próprio participante, ou seu representante legal) 
Sugerimos-lhe que conserve esta cópia do documento, ficando a outra cópia na 
posse do responsável do projecto. 
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